News

TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB

Kevin DA, Meujo DAF, Hamann MT. Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites. Expert Opinion on Drug Discovery 2009 Feb;4(2):109-146(38). doi:10.1517/17460440802661443.

During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Monensin, a known class of antibiotics discovered in 1967, is a polyether ionophore. These compounds are naturally occurring materials generated by a large range of bacteria (e.g. Streptomyces, Actinomadura). They are highly lipophilic with a high molecular weight (500-1000 amu). Their spectrum of activity is quite broad and includes antibacterial, antifungal, antiparasitic, antiviral, antineoplastic activities, anti-inflammatory, immunoregulatory, and CNS activity. Key points to consider regarding polyether ionophores and their use as anti-tuberculosis agents are:

  • These compounds are well-known, naturally occurring, inexpensive, broad spectrum bioactive materials currently used extensively in veterinary medicine against parasites and in food production as a growth promotant.
  • The mechanism of action is through the disruption of ion gradients across cellular membranes.
  • There may be opportunity for synergism with other energy metabolism inhibitors (i.e., TMC207 or clofazimine).
  • There is evidence these compounds exhibit anti-HIV activity (article) and could be used in HIV co-infected TB patients.
  • There is evidence of some cardiovascular and hemodynamic toxicities but these are poorly understood and appear to be species-dependent.

Additional TB R&D News:

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

Short-course Chemotherapy with TMC-207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection

Incidence of Moxifloxacin Resistance in Clinical Mycobacterium tuberculosis Isolates in Houston, Texas

Next Steps for Tenofovir Gel: Conrad And TIA Sign License Agreement

SCYNEXIS and TB Alliance Sign HEOS Software Agreement

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...